Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function
Foster Y, Grant M, Thomas S, Cameron B, Raiff D, Corbet K, Ferreri C, Horwitz M. Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function. Blood 2018, 132: 4594. DOI: 10.1182/blood-2018-99-113189.Peer-Reviewed Original ResearchLong-term renal functionAcute kidney failureAcute kidney injuryChronic kidney diseaseRenal functionChronic GVHDNephrotoxic drugsHuman herpes virus-6 (HHV-6) reactivationAllogeneic hematopoietic cell transplantEnd-stage renal diseaseAlternative donor graftsHHV-6 viremiaUnadjusted median survivalRetrospective cohort studyHematopoietic cell transplantTransplant-related factorsGlomerular filtration rateSerum creatinine valuesMultivariate logistic regressionCKD-EPI equationUmbilical cord bloodManual chart reviewAcute GVHDEGFR declineLower eGFRs